AML with recurrent genetic abnormalities constitute a large group of AML subtypes, which comprises: APL with t(15;17)(q24.1;q21.2)/PML::RARA, AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11, AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A, AML with t(6;9)(p22.3;q34.1)/DEK::NUP214, AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1), AML with other rare recurring translocations, AML with mutated NPM1, AML with in-frame bZIP mutated CEBPA, and AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. This evidence concerns the gene KMT2A and acute myeloid leukemia.